American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010

In 2009, the American Cancer Society (ACS) Prostate Cancer Advisory Committee began the process of a complete update of recommendations for early prostate cancer detection. A series of systematic evidence reviews was conducted focusing on evidence related to the early detection of prostate cancer, t...

Full description

Saved in:
Bibliographic Details
Published inCA: a cancer journal for clinicians Vol. 60; no. 2; pp. 70 - 98
Main Authors Wolf, Andrew M. D, Wender, Richard C, Etzioni, Ruth B, Thompson, Ian M, D'Amico, Anthony V, Volk, Robert J, Brooks, Durado D, Dash, Chiranjeev, Guessous, Idris, Andrews, Kimberly, DeSantis, Carol, Smith, Robert A
Format Journal Article
LanguageEnglish
Published Hoboken Am Cancer Soc 01.03.2010
Wiley Subscription Services, Inc., A Wiley Company
Wiley Subscription Services, Inc
Subjects
Antineoplastic Agents, Hormonal - adverse effects
Anxiety
Biopsy, Fine-Needle - adverse effects
Continuity of Patient Care
Decision Making
Early Detection of Cancer - standards
Evidence-Based Medicine
Guidelines
Humans
Life Expectancy
Male
Mass Screening - standards
Medical screening
Mens health
Phlebotomy - adverse effects
Physical Examination - methods
Prostate - pathology
Prostate cancer
Prostate-Specific Antigen - blood
Prostatectomy - adverse effects
Prostatectomy - methods
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - epidemiology
Prostatic Neoplasms - therapy
Radiotherapy - adverse effects
Randomized Controlled Trials as Topic
Rectum
Reference Values
Risk Assessment
Risk Factors
SEER Program
Sexual Dysfunction, Physiological - etiology
Systematic review
Uncertainty
United States - epidemiology
Urinary Incontinence, Stress - etiology
United States
United States > US
Online AccessGet full text

Cover

More Information
Summary:In 2009, the American Cancer Society (ACS) Prostate Cancer Advisory Committee began the process of a complete update of recommendations for early prostate cancer detection. A series of systematic evidence reviews was conducted focusing on evidence related to the early detection of prostate cancer, test performance, harms of therapy for localized prostate cancer, and shared and informed decision making in prostate cancer screening. The results of the systematic reviews were evaluated by the ACS Prostate Cancer Advisory Committee, and deliberations about the evidence occurred at committee meetings and during conference calls. On the basis of the evidence and a consensus process, the Prostate Cancer Advisory Committee developed the guideline, and a writing committee drafted a guideline document that was circulated to the entire committee for review and revision. The document was then circulated to peer reviewers for feedback, and finally to the ACS Mission Outcomes Committee and the ACS Board of Directors for approval. The ACS recommends that asymptomatic men who have at least a 10‐year life expectancy have an opportunity to make an informed decision with their health care provider about screening for prostate cancer after they receive information about the uncertainties, risks, and potential benefits associated with prostate cancer screening. Prostate cancer screening should not occur without an informed decision‐making process. Men at average risk should receive this information beginning at age 50 years. Men in higher risk groups should receive this information before age 50 years. Men should either receive this information directly from their health care providers or be referred to reliable and culturally appropriate sources. Patient decision aids are helpful in preparing men to make a decision whether to be tested. CA Cancer J Clin 2010;60:70–98. © 2010 American Cancer Society, Inc.
Bibliography:http://CME.AmCancerSoc.org
Members of the American Cancer Society Prostate Cancer Advisory Committee were asked to disclose relationships, including potential financial conflicts of interest. The following was disclosed: G. Chodak has served on the advisory board for Watson Pharmaceuticals and Ferring Pharmaceuticals; V. Simons has served as a consultant to the State of New Jersey Office of Cancer Control and Prevention for their Cancer Education and Early Detection program, has served as co‐investigator to various university‐based research studies on reaching African American men to promote disease risk awareness and/or early detection, and is the recipient of educational grants from AstraZeneca, Sanofi‐Aventis, GTx, Genentech, and Abbott Oncology for a Patient/Professional Symposium Educational Program (see Form 990 at
http://www.guidestar.org
To earn free CME credit or nursing contact hours for successfully completing the online quiz based on this article, go to
http://cajournal.org
http://cacancerjournal.org
for more information); I. Thompson has served as a consultant to Mission Pharmacal and to Veridex for a new biomarker that is being tested for future application to the FDA for detection of prostate cancer. All revenues from this consultancy are transmitted to the University of Texas Health Science Center. He has also received grant support from the Early Detection Research Network, NCl. No other potential conflicts relevant to this article were reported.
American Cancer Society Prostate Cancer Advisory Committee: Andrew M. D. Wolf, MD (Chair), Associate Professor of Medicine, University of Virginia School of Medicine, Charlottesville, VA; Claudia R. Baquet, MD, MPH, Associate Dean for Policy and Planning and Director, Center for Health Disparities, University of Maryland School of Medicine, Baltimore, MD; Gerald Chodak, MD, Chicago, IL; Jennie Cook, American Cancer Society National Assembly Life Member, Larkspur, CA; Anthony V. D'Amico, MD, PhD, Chair, Division of Genitourinary Radiation Oncology, Dana‐Farber Cancer Institute and Professor of Radiation Oncology, Harvard Medical School, Boston, MA; Ruth B. Etzioni, PhD, Full Member, Program in Biostatistics and Biomathematics, Fred Hutchinson Cancer Research Center, Seattle, WA; Thomas D. Fogel, MD, Cabrillo Radiation Oncology Medical Center and Coastal Radiation Oncology Medical Group, Ventura, CA; Paul A. Godley, MD, PhD, MPP, Professor, Hematology/Oncology, University of North Carolina School of Medicine and Member, Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Cynthia M. LeBlanc, EdD, MA, Vice‐chair, American Cancer Society National Board of Directors, Richmond, CA; Terry Mason, MD, Chief Medical Officer, Cook County Health and Hospitals System, Chicago, IL; Viraj Master, MD, PhD, Assistant Professor of Urology, Emory University School of Medicine, Atlanta, GA; Andrew L. Salner, MD, Director, Department of Radiation Oncology and Director, Cancer Program, Hartford Hospital, Hartford, CT; Virgil H. Simons, Founder and President, The Prostate Net, Secaucus, NJ; Ian M. Thompson, Jr., MD, Chairman and Professor, Department of Urology, The University of Texas Health Science Center, San Antonio, TX; and Richard C. Wender, MD, Chair and Alumni Professor, Department of Family and Community Medicine, Thomas Jefferson University Medical College, Philadelphia, PA
.
Available online at
and
DISCLOSURES
ACS Staff (Atlanta, GA): Kimberly Andrews, Research Associate, Cancer Control Science Department; Durado D. Brooks, MD, MPH, Director, Prostate and Colorectal Cancers, Cancer Control Science Department; J. Leonard Lichtenfeld, MD, MACP, Deputy Chief Medical Officer; Robert A. Smith, PhD, Director, Cancer Screening, Cancer Control Science Department.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Instructional Material/Guideline-3
ObjectType-Feature-4
content type line 23
ObjectType-Review-1
ISSN:0007-9235
1542-4863
DOI:10.3322/caac.20066